STAT+: Lilly wins approval for once-weekly insulin shot
The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an alternative to daily long-acting insulin injections.
<p>The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an alternative to daily long-acting insulin injections.</p>